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Proteinase 3 (Pr3), the main target of 
anti neutrophil cytoplasmic antibodies 
(ANCAs), is a neutrophil serine protease that 
may be constitutively expressed at the surface of 
quiescent circulating neutrophils. This raises the 
question of the simultaneous presence in the 
circulation of constitutive membrane-bound Pr3 
(mPr3) and its plasma inhibitor alpha-1-
antiproteinase inhibitor α1-Pi. We have looked 
at the fate of constitutive mPr3 at the surface of 
circulating blood neutrophils and of induced 
mPr3 on triggered neutrophils. We found 
significant Pr3 activity at the surface of 
activated neutrophils but not at the surface of 
quiescent neutrophils whatever the constitutive 
expression. This suggests that constitutive mPr3 
is enzymatically inactive or its active site is not 
accessible to the substrate.  Supporting this 
conclusion, we have not been able to 
demonstrate any interaction between 
constitutive mPr3 and α1-Pi, whereas induced 
mPr3 is cleared from the cell surface when 
activated cells are incubated with this inhibitor. 
But, unlike membrane-bound elastase that is 
also cleared from the surface of activated cells, 
mPr3 remained bound to the membrane when 
inhibited by elafin or by a low Mr chloromethyl 
ketone inhibitor, which shows that it binds more 
tightly to the neutrophil membrane. mPr3 may 
thus be present at the surface of circulating 
neutrophils in an environment replete with α1-
Pi. The permanent presence of inactive Pr3 at 
the surface of quiescent neutrophils may explain 
why Pr3 is a major target of ANCAs, whose 
binding activates neutrophils and triggers 
inflammation, as in Wegener’s granulomatosis.  
(244 words) 
  
Proteinase 3 (Pr3) is a neutral serine 
protease (NSP) that is stored in the granules of 
circulating neutrophils (1,2) and has been more 
recently located within secretory vesicles (3). Pr3, 
like its homologues neutrophil elastase (HNE) and 
cathepsin G (CG), participates in the intracellular 
degradation of phagocytized pathogens at 
inflammatory sites in combination with 
microbicidal peptides and the membrane-associated 
NADPH-oxidase system (4). All three NSPs are 
also released from activated neutrophils and help 
destroy extracellular matrix components and 
regulate innate immunity, inflammation and 
infection (5). Though NSPs are structurally and 
functionally related and are synthesized similarly 
(6), Pr3 differs from the other two by its bimodal, 
genetically determined, expression on the cell 
surface of quiescent neutrophils (7,8). Thus, each 
individual has two subsets of neutrophils: mPr3high 
and of mPr3low, whereas HNE and CG are not 
present in significant amount at the surface of 
resting neutrophils. Pr3 also differs from the other 
two NSPs by its storage within secretory vesicles 
that readily fuse with the plasma membrane (3). 
But it is not clear that this explains why Pr3 is 
constitutively expressed at the surface of a 
subpopulation of quiescent neutrophils. Supporting 
this hypothesis, it has been recently demonstrated 
that CD177 (also called NB1), which is also stored 
in secretory vesicles and has a bimodal membrane 
expression, is present on the plasma membrane of 
the same subset of neutrophils as Pr3 (9,10).  
The presence of Pr3 on the surface of 
quiescent neutrophils would favour neutrophil 
activation by anti-neutrophil cytoplasmic 
autoantibodies (ANCAs) during Wegener’s 
granulomatosis (WG) (11). This explains why this 
protease, unlike HNE and CG, is a risk factor for
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this autoimmune disease characterized by 
necrotizing inflammation particularly of the 
respiratory tract, kidneys, and by small vessel 
vasculitis (12). Binding of anti-Pr3 antibodies to 
TNFα-primed neutrophils is impaired by α1-Pi 
(13) which suggests that mPr3 activity and the 
protease-antiprotease balance are involved in 
neutrophil activation during WG.  
 Measuring the Pr3 activity on the cell 
surface of quiescent and activated neutrophils 
requires specific substrates of Pr3 that were not 
available until recently (14,15). Because of the 
storage of Pr3 in both secretory vesicles and 
primary granules and the presence of constitutive 
Pr3 at the surface of resting neutrophils, we have 
determined whether both constitutive and induced 
Pr3 are enzymatically active when bound to the cell 
surface, and how they are regulated by protease 
inhibitors. Pr3 activity is controlled by a variety of 
natural inhibitors, the most important of which are 
α1-Pi, elafin/trappin2 and monocyte neutrophil 
elastase inhibitor (MNEI). But none is specific for 
this protease, so that it cannot be specifically 
targeted in vivo or ex vivo. We have previously 
shown that mHNE is rapidly cleared from the 
surface of activated neutrophils by α1-Pi and by 
EPI-hNE4, a low Mr recombinant inhibitor, with 
which it forms soluble, inactive complexes (16,17). 
This raises the question of how mPr3 can be 
targeted by autoantibodies in the presence of α1-Pi, 
which efficiently inhibits its soluble form, though 
more slowly than it does HNE (18). We answered 
this question by investigating the enzymatic 
properties of mPr3 and its sensitivity to inhibitors.  
The behavior of mPr3 clearly differs from that of 
mHNE, which explains why it may be a 
preferential target for autoantibodies and so 
contributes to the pathogenicity of Wegener`s 
disease. 
 
EXPERIMENTAL PROCEDURES 
Materials - Human proteinase 3 (EC 
3.4.21.76), human neutrophil elastase (EC 
3.4.21.37) and human α1-Pi were obtained from 
Athens Research & Technology (Athens, GA, 
USA). The calcium ionophore A23187, elafin and 
EGTA were from Sigma-Aldrich (St. Quentin 
Fallavier, France). The specific elastase inhibitor 
EPI-hNE4 was a kind gift from F. Saudubray 
(Debiopharm, Lausanne, Switzerland). N,N-
dimethylformamide was from Merck Chimie 
(Fontenay sous Bois, France). MeO-Suc-AAPA-
CMK was from Enzyme System Products 
(Livermore, CA, USA). Polymorphprep™ and 
Lymphoprep™ were purchased from AbCys (Paris, 
France). Mouse IgG1 and goat F(ab’)2 fragment 
anti-mouse IgG (Fcγ)-FITC were from Beckman 
Coulter (Roissy, France). Anti-Pr3 mAbs (clone 
MCPR3-2) were purchased from Euromedex 
(Souffelweyersheim, France).  
Isolation of blood neutrophils - Human 
neutrophils were purified from 16 ml samples of 
peripheral blood collected from healthy volunteers 
into EDTA-containing tubes essentially as 
previously reported (19). The neutrophil pellet 
recovered after lysing the erythrocytes was washed 
twice in PBS containing 4 mM EGTA. Cell 
viability was checked by trypan blue exclusion. 
Neutrophils were activated by suspending ~3 x 106 
cells/ml in PBS containing 1 mM CaCl2 and 1 mM 
MgCl2 and incubating them with A23187 (1 µM 
final) for 15 min at 37°C (19). The resting and 
activated neutrophils were suspended in PBS-
EGTA. We used activation with the calcium 
ionophore A23187 to optimize mPr3 exposure at 
the cell surface  (20) and to avoid production of 
neutrophil extracellular traps (NETs), as occurs 
when IL-8 or phorbol esters are used, since they 
may interfere with flow cytometry analyses and 
enzyme assays (21) 
Flow cytometry analysis - Flow cytometry 
was performed on a Beckman Coulter XL flow 
cytometer equipped with a 488 nm argon laser and 
analyses were performed essentially as described in 
(19). To analyze specifically interaction of 
inhibitors with mPr3, mHNE was cleared from the 
cell surface by pre-incubating cells (2 x 105 - 5 x 
105 quiescent or activated neutrophils) with a molar 
excess of EPI-hNE4 (5 x 10-8 to 5 x 10-7 M) (17). 
Any mPr3 antigen at the neutrophil surface was 
then detected prior to and after α1-Pi or elafin (5 x 
10-7 to 10-6 M final) or CMK (10 mM final) 
treatment, incubating the cells with monoclonal 
anti-Pr3 antibodies (clone MCPR3-2, Euromedex) 
diluted 1:50, for 30 min at 4°C. After washing in 
PBS-1, cells were incubated with FITC-conjugated 
F(ab’)2 fragments from goat anti-mouse IgG 
(diluted 1:50) for 30 min at 4°C. Mouse IgG1 
isotype controls (diluted 1/50) were performed 
under the same experimental conditions. Data were 
recorded for at least 10,000 events and analyzed 
with the Expo32 software (Beckman Coulter, 
France).                                                                                                       
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Enzyme assays - The activities of free and 
membrane-bound proteases were measured in 
PBS-EGTA. Free Pr3 and HNE were titrated with 
α1-Pi, the titer of which had been determined using 
bovine trypsin titrated with p-nitrophenyl-p'-
guanidinobenzoate (22). mPr3 and mHNE 
activities were quantified by comparing the rates of 
hydrolysis of their specific FRET substrates (Abz)-
VADnorVADRQ-(EDDnp) and (Abz)-
APEEIMRRQ-(EDDnp) (15,23) with that of 
titrated commercial proteases under the same 
experimental conditions. The concentration of 
Abz-peptidyl-EDDnp substrates  was determined 
by measuring the absorbance at 365 nm, using 
ε365nm = 17,300 M–1 cm–1 for EDDnp. Unactivated 
and activated (2 x 105 to 5 x 105 cells) neutrophils, 
or purified proteases used as controls, were 
incubated with 15 µM of specific substrate in 
polypropylene microplate wells selected for their 
low binding properties (Hard-Shell Thin-Wall 
Microplates; MJ Research) at room temperature in 
activity buffer (10 mM PBS-4mM EGTA, pH 7.4). 
The fluorescence was recorded at λex = 320 nm and 
λem = 420 nm using a microplate fluorescence 
reader (Spectra Max Gemini; Molecular Devices) 
under continuous stirring.    
Chromatographic procedures and analysis 
of peptide products - Once the enzyme reaction 
was complete, the reaction medium was incubated 
with 4 vol. of absolute ethanol for 15 min on ice 
and centrifuged at 13,000 g for 10 min. The 
supernatant containing the hydrolysis products was 
recovered, air-dried under vacuum and dissolved in 
200 µl of 0.01% trifluoroacetic acid (v/v). 
Hydrolysis fragments were purified by rp-HPLC 
on a C18 column (2.1 mm X 30 mm or 2 mm X 33 
mm, Uptisphere), using a P200 pump coupled to a 
Spectrasystem UV3000 detector (Thermo 
Separation Products), at a flow rate of 0.3 ml/min, 
with a linear (0-60%, v/v) gradient of acetonitrile 
in 0.01% trifluoroacetic acid over 20 min. Eluted 
peaks were monitored at three wavelengths (220, 
320 and 360 nm) simultaneously, which allowed 
the direct identification of EDDnp-containing 
peptides prior to sequencing. Cleavage sites were 
identified by N-terminal sequencing in an Applied 
Biosystems Procise 494 protein sequencer attached 
to a model 140C Micro-gradient System and a 
610A Data Analysis System with the chemicals 
and program recommended by the manufacturer. 
 Release of membrane-bound proteases - 
The release of mPr3 and mHNE into PBS was 
checked by incubating cells (3 x 106 cells/ml) in 
buffer for up to 1 h and measuring the peptidase 
activities in supernatants cleared of cells by 
centrifugation for 5 min at 500 g. Cell pellets were 
suspended in the same buffer, and membrane-
bound activity was measured using the same 
procedure. The procedure was repeated using the 
same buffer supplemented with 1.5 M NaCl. 
Neutrophils were kept for 1 h at room temperature 
or 24 h at 37°C under gentle stirring, collected by 
centrifugation at 500 g for 15 min, and suspended 
in PBS containing 1.5 M NaCl (final). The Pr3 and 
HNE activities in the supernatants of cells were 
measured and compared with the activities on 
unfractionated treated cells.    
  Inhibition of mPr3 by α1-Pi, Elafin and 
MeO-Suc-AAPA-CMK - Inhibition of mPr3 by α1-
Pi or elafin was analyzed under pseudo-first order 
conditions using a 1000-fold molar excess of 
inhibitor. Activated neutrophils (2 x 105 to 5 x 105 
cells) corresponding to 5 x 10–10 M to 10-9 M  
active purified Pr3, were pre-incubated with EPI-
hNE4 (10-8 M to 5 x 10-7 M) for 5 min at room 
temperature. The Pr3 substrate (15 µM) and α1-Pi 
or elafin (5 x 10-7 M to 10-6 M) were added at the 
same time to the reaction medium and fluorescence 
was recorded continuously every 24 sec for up to 
4,000 sec. A control was made to check that 
mHNE remained fully inhibited by EPI-hNE4. The 
inhibition of mPr3 by α1-Pi or elafin was also 
checked under the same experimental conditions 
by pre-incubating the EPI-hNE4-treated cells with 
α1-Pi or elafin for 4,000 sec before adding the Pr3 
substrate. mPr3 was also inhibited by incubating 
the cells with 10–4 M MeO-Suc-AAPA-CMK for 
2h. Controls using free Pr3 were performed under 
the same experimental conditions. 
RESULTS 
 
Enzymatic activity and stability of 
proteinase 3 on the cell surface of purified 
neutrophils - We first determined the Pr3 on the 
surfaces of resting and activated neutrophils from 
healthy donors by flow cytometry with anti-Pr3 
antibodies. The resting neutrophils had a 
genetically determined distribution of the protease 
that resulted in a bimodal mPr3 expression (Fig. 1). 
The mPr3 activity remains low, generally  below 
the detection limit (10-10M) whatever the 
percentage of mPr3high  quiescent cells, and despite 
the high cell concentration (300,000 cells/150 µL). 
Any proteolytic activity detected was due to the 
 4 
partial activation of quiescent neutrophils that 
occurs during cell purification. This was confirmed 
by the parallel recording of a basal neutrophil 
elastase activity that should not be present at the 
surface of quiescent neutrophils (not shown). 
These results strongly suggest that constitutive 
mPr3 is inactive. All the purified neutrophils had 
more Pr3 at their surface after they had been 
activated with the calcium ionophore A23187 (Fig. 
1) or after incubation for 2 hours in PBS at room 
temperature (not shown). The Pr3 activity in the 
cell suspensions was increased by a factor of 5 to 
20 (Fig. 1). We quantified the mPr3 concentration 
in the cell suspension by comparing the rate of 
hydrolysis of Abz-VADnorVADRQ-EDDnp by 
activated cell suspensions (300,000 cells/150 µL) 
with that of free, titrated Pr3. For this purpose, we 
assumed that mPr3 and soluble Pr3 hydrolyse their 
synthetic low Mr substrate similarly. The apparent 
concentration of mPr3 varied from <0.1 nM to 4 
nM, and this concentration was independent of the 
percentage of mPr3high resting cells before 
activation (Fig. 1).  
 We ensured that no other neutrophil 
protease had cleaved the Pr3 substrate by checking 
that there was a single cleavage site at the expected 
norV-A bond of the FRET substrate. This was 
done by fractionation of the supernatant by rp-
HPLC and N-terminal sequencing of the EDDnp-
containing fragment (Fig. 2). We next measured 
the Pr3 activity in the supernatant after 
centrifuging the cell suspension at 500 g for 5 min 
to ensure that the enzyme activity was mainly due 
to membrane bound Pr3. About 25% of total 
activity was recovered in this supernatant (Fig. 3) 
and this percentage remained unchanged 
throughout a two hour incubation before 
centrifugation. We checked by flow cytometry that 
the substrate did not release mPr3 from the 
membrane (not shown). We also found that mPr3 
was not released from the surface of activated cells 
placed in buffer containing 1.5 M NaCl, whereas 
almost all the mHNE was released (Fig. 3). Thus, 
mPr3 binds differently and more tightly to the cell 
surface than does mHNE. This raises the question 
of the inhibition of mPr3 at the cell surface. We 
investigated the interaction between constitutive 
and induced mPr3 with natural inhibitors like α1-
Pi and elafin, and synthetic inhibitors in order to 
better understand the function of these two mPr3 
populations 
 
 Inhibition of membrane-bound Pr3 by 
natural and synthetic inhibitors - We first checked 
whether active Pr3 at the membrane surface of 
activated neutrophils was inhibited by α1-Pi, its 
main natural inhibitor. Because α1-Pi is not 
specific for Pr3 and preferentially inhibits HNE 
(18), we cleared mHNE from the cell surface using 
a molar excess of the low Mr HNE-specific 
inhibitor EPI-hNE4 (17). We ensured by kinetic 
analysis that no HNE activity remained in the 
reaction mixture using an HNE-specific substrate, 
and that the Pr3 activity remained unchanged after 
EPI-hNE4 treatment (not shown). We then added a 
large molar excess of α1-Pi (0.5-1 µM final, close 
to its pathophysiological plasma concentration) to a 
suspension of triggered neutrophils (200-500 x 103 
cells) whose mPr3 activity was 0.2 nM and 1 nM. 
We used soluble Pr3 as a control and adjusted it to 
obtain the same rate of hydrolysis. The rates of 
inhibition of soluble and mPr3 were then recorded 
under pseudo-first order conditions (I>>E) in the 
cell suspension and in the control. mPr3 was 
inhibited almost as rapidly as the soluble Pr3, but 
inhibition was not complete after one hour 
continuous recording (Fig. 4A). Because Pr3 is 
inhibited by α1-Pi more slowly than HNE, this was 
probably due to competition between the inhibitor 
and substrate for binding to newly exposed Pr3 
molecules at the membrane surface of activated, 
unfixed cells.  We confirmed this by incubating 
cells with the inhibitor for one hour before adding 
the substrate. No activity was recorded under these 
conditions. The same result was obtained using a 
large molar excess of elafin (Fig. 4B) that fully 
inhibited mPr3 only when it was preincubated with 
the cell suspension, but not during an assay in the 
presence of the substrate. A molar excess of low 
Mr chloromethylketone irreversible inhibitor MeO-
Suc-AAPA-CMK  also inhibited about 90% mPr3 
activity after two hours (insert of Fig. 4C). The 
next question was whether the newly-formed 
mPr3-inhibitor complexes remain at the membrane 
surface.  
 
 Fate of membrane bound Pr3-inhibitor 
complexes - We studied the fate of mPr3-α1Pi 
complexes by flow cytometry. Activated cells were 
first treated with EPI-hNE4 as before to remove m 
HNE, and the inactivity of HNE and activity of Pr3 
were checked.  A molar excess of α1-Pi was added 
to activated cells, which were then incubated with 
the MCPR3-2 anti-Pr3 mAb. This mAb was used 
because western blotting showed that it still 
recognized Pr3 after binding to α1-Pi, despite the 
drastic structural rearrangements that occur during 
the formation of the complex between serpins and 
their target proteases. The fluorescent peak was not 
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displaced by excess α1-Pi using mPr3high quiescent 
cells bearing constitutive mPr3 on their surface 
(Fig. 4D). This confirmed that constitutive mPr3 
does not form an irreversible complex with the 
inhibitor. But whether this is due to an 
enzymatically inactive protease, or to impaired 
access to the active site as a result of a different 
exposure of constitutive mPr3 remains to be 
determined. The fluorescent peak was displaced 
when activated cells were incubated with α1-Pi, 
which strongly suggests that induced Pr3 is 
removed from the membrane when the complex is 
formed (Fig. 4E). But the fluorescent peak was not 
displaced when Pr3high quiescent cells and triggered 
cells were incubated with elafin (Fig. 4F-G) or 
with the low Mr chloromethyl ketone inhibitor 
MeO-Suc-AAPA-CMK that also inhibits Pr3 at the 
surface of activated cells (Fig. 4C). We conclude 
that complexes formed between induced mPr3 and 
low Mr inhibitors remain at the cell surface. This 
differs from mHNE, which is cleared from the 
surface of triggered neutrophils by incubation with 
a low Mr recombinant inhibitor (17). 
 
DISCUSSION 
 
Pr3 is exposed at the surface of quiescent 
circulating neutrophils in a genetically determined 
fashion, unlike HNE or CG (7). We have 
previously developed Pr3 FRET substrates that can 
measure subnanomolar Pr3 concentrations (15,23), 
one of them was used here to measure the Pr3 
activity at the surface of quiescent and triggered 
neutrophils. When used at a concentration of 
300,000 cells/150µL, only activated neutrophils    
showed any significant activity against the Pr3-
specific FRET substrate Abz-VADnorVADRQ-
EDDnp. Some samples of quiescent cells retained 
detectable activity at their surface but this was due 
to the propensity of neutrophils to become 
activated, especially during the erythrocyte 
removing step of their purification (24), and  to the 
great sensitivity of the Pr3 FRET substrate (19). 
But this activity was independent of the mPr3 
status of the cell population since some mPr3high 
cell suspensions had no detectable mPr3 activity. 
We conclude that constitutive mPr3 is inactive. 
This is why Pr3 may be present at the surface of 
circulating quiescent neutrophils without 
interacting with α1-Pi, in spite of its huge plasma 
concentration.   
Assuming that  membrane binding at the 
surface of triggered cells does not alter mPr3 
kinetic properties, induced mPr3 would be about 
ten times less concentrated than mHNE  based on 
the rate of hydrolysis of its specific FRET 
substrate. But there is no specific pseudo 
irreversible Pr3 inhibitor presently available that 
would allow us to titrate mPr3 and to answer this 
question unambiguously, as we did for mHNE 
(16). Thus the enzymatic properties of mPr3 might 
be altered because of the way it is bound to the cell 
membrane. There is considerable evidence that 
mPr3 and mHNE bind differently to the membrane. 
For example, high salt concentrations lead to the 
rapid release of mHNE from triggered neutrophil 
membranes, but not to the release of mPr3. There 
is also a large cluster of positive charges at the 
HNE surface which  is interrupted in Pr3, making it 
more electronegative than HNE (15). But mPr3 
binding to neutrophil membranes is not only 
charge dependent (25), since anchoring to the 
hydrophobic membrane leaflet (26-28) and 
covalent attachment to CD16/ FcgRIIIb (29 ,30) 
have been reported. Further, mPr3 colocalizes with 
the adhesion molecule CD11b/CD18 (β2 integrin) 
(31). The glycosylphosphatidylinositol-anchored 
glycoprotein CD177 (NB1 antigen), that is 
bimodally expressed and is present on the same 
subset of neutrophils as Pr3 (9), has also been 
shown to mediate the exposure of mPr3 at the cell 
surface (32). This binding probably occurs via the 
single hydrophobic cluster on the surface of Pr3, 
but not on NE or CG (33). The fact that the NB1 
antigen is stored in secretory vesicles and 
secondary granules, but not in primary granules (9) 
supports the idea that constitutive mPr3 originates 
from secretory granules while induced Pr3, that is 
coexpressed with HNE and CG, is mainly stored in 
primary granules. This different storage within the 
cell could well result in different binding modes 
and/or changes in the protease structure at the cell 
surface that alter its enzymatic properties but this 
needs further investigation. It is clear that the NB1 
antigen is not the only binding site for mPr3 (34). 
von Vietinghoff et al (10) found that there is an 
NB1-independent presentation early during 
differentiation in addition to membrane Pr3 
presentation via the NB1 receptor. A proform that 
escapes granular targeting has been demonstrated 
during synthesis (35). Constitutive Pr3 could be an 
enzymatically inactive proform that still contains 
an amino-terminal propeptide and is secreted 
during neutrophil maturation. Constitutive Pr3 
could also be a proteolytically degraded and 
inactivated protease that still binds mAbs and c-
ANCAs.  
 We confirmed that constitutive and 
induced mPr3 have different enzymatic properties 
by studying their interactions with α1-Pi. The 
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simultaneous presence of active mPr3 and its 
inhibitors in the same physiological compartment 
has been explained by the resistance of mPr3 to 
naturally occurring inhibitors (20). But those 
experiments were done using fixed cells incubated 
with purified Pr3. Our present study shows that 
induced mPr3 is inhibited by α1-Pi and by low Mr 
inhibitors. Nevertheless, α1-Pi inhibits HNE faster 
than Pr3 (6) which means that transient 
extracellular Pr3 activity may remain when 
competition occurs between natural substrates and 
its main physiological inhibitor. Flow cytometry 
studies showed that mPr3 is cleared from the 
surface of triggered neutrophils by α1-PI, as is 
membrane-bound elastase (16). But mPr3 is not 
released from the cell surface by a canonical 
inhibitor like elafin or a low Mr 
chloromethyketone inhibitor, although these 
inhibitors fully inhibited its enzymatic activity. 
This again indicates that the active protease is more 
tightly bound to the neutrophil membrane than is 
mHNE, which is released form cell surfaces by its 
low Mr inhibitor EPI-hNE4 (17). Our flow 
cytometry studies also show that α1-Pi does not 
release constitutive mPr3 from quiescent 
neutrophils isolated from individuals having a 
significant population of mPr3high cells. This 
confirms that constitutive mPr3 is enzymatically 
inactive.      
Constitutive mPr3 is reported to be a 
putative pathogenic factor in ANCA-associated 
vasculitis and chronic inflammatory diseases (36, 
37), although this is still a matter of debate (38). 
But the binding of Pr3-ANCAs to cell surface Pr3, 
which results in neutrophil activation, remains the 
most attractive explanation for the contribution of 
these antibodies to the pathogenesis of Wegener’s 
granulomasis (39). For mPr3 to interact with 
ANCAs, it should be present at the cell surface in 
an environment replete with α1-Pi that can bind to 
its active site and remove it from the cell surface. 
But we show here that constitutive mPr3 does not 
interact with α1-Pi, so that it can remain at the 
surface of quiescent circulating neutrophils even in 
the presence of huge amounts of inhibitor. 
Constitutive mPr3 could still interact with 
circulating ANCAs under these conditions, which 
explains why mPr3high patients are more 
susceptible to a relapse during WG than are 
patients with low concentrations of constitutive 
mPr3 (11). A previous study reports that ANCAs 
do not bind to circulating neutrophils in WG 
patients  (40), but this lack of binding could be due 
to the ANCAs-induced activation of neutrophils 
and their subsequent adhesion to endothelium (38). 
 TNF-α primed neutrophils  incubated with 
excess α1-Pi are significantly less sensitive to 
activation by an anti-Pr3 mAb, suggesting that the 
inhibitor impairs mAb binding (13). Because 
induced mPr3 is present at the surface of primed 
neutrophils in addition to constitutive mPr3, this 
could be explained by the removal of induced 
mPr3 from the cell surface by α1-Pi, as was shown 
using cells that stably expressed the NB1 receptor 
(33). This also agrees with the recent observation 
that Pr3 is no longer present on neutrophil 
membranes when TNF-α activation is suppressed 
by α1-Pi (41). Other results show that Pr3-ANCAs 
interfere with the enzymatic activity of Pr3 but 
they were obtained using soluble Pr3 rather than 
membrane-bound Pr3 (42). Thus, there is no 
formal proof that the enzymatic activity of mPr3 
modulates activation of neutrophils by anti-Pr3. 
α1-Pi preferentially inhibits HNE, so that mPr3 is 
not its main target (18). Hence, designing a serpin-
like inhibitor that specifically removes induced 
mPr3 would help clarify the roles of constitutive 
and induced mPr3 in the pathogenicity of 
vasculitides, and serve as a putative therapeutic 
agent for controlling the neutrophil-induced 
inflammation that occurs in WG and related 
diseases. 
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FIGURES LEGENDS 
 
Fig. 1: Distribution and activity of membrane-bound proteinase 3 at the surface of quiescent and 
activated blood neutrophils. (Top) Box plot (n=12) of Pr3 activity measured by incubating 300,000 
cells/150 µL with the FRET substrate Abz-VADnorVADRQ-EDDnp. The lowest concentration of 
Pr3 activity that can be quantified is 0.1 nM. The width of the boxes reflects the percentage of  
mPr3high cells in each sample of quiescent and activated neutrophils, determined by flow cytometry. 
The selected blood samples are representative of the distribution of mPr3 in the population, which 
includes only 3% of monomodal mPr3low individuals (43). (Bottom) Flow cytometry analysis of 
representative neutrophil preparations from three healthy donors with different bimodal mPr3 
distributions before (gray peaks) and after (black peaks) activation with the calcium ionophore 
A23187, and labeling with the anti-Pr3 mAbs (clone MCPR3-2). The thin lines represent non-
specific binding of isotype control IgG. Arrows indicate the % of mPr3high quiescent neutrophils.  
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The concentration of active mPr3 in each sample of quiescent neutrophils is indicated in nM. It 
shows no correlation between the high/low mPr3 status and enzyme activity. 
 
Fig. 2: Identification by rp-HPLC of the cleavage site within Abz-VADnorVADRQ-EDDnp FRET 
substrate before (A) and after hydrolysis by free proteinase 3 (B) and purified activated neutrophils 
(C). The cleavage sites were identified by N-terminal sequencing of the EDDnp-containing 
fragments having an absorbance peak at 360 nm (not shown). 
 
Fig. 3: Pr3 activity at the surface and in the supernatant of activated neutrophils. About 25% of the 
total Pr3 activity is released spontaneously when cells are suspended in PBS for at least 120 min and 
no further release occurs following incubation with 1.5 M NaCl, whereas almost all the membrane-
bound HNE is released into the supernatant after incubation with NaCl. 
   
Fig. 4: Fate of Pr3 at the neutrophil surface. Activities of soluble Pr3 and mPr3 prior to and after 
adding a molar excess of α1-Pi (A) or elafin (B). Inserts show the percentages of inhibition after 
incubation for one hour (mean of 3 analyses).  Neutrophil samples in A and B are from two different 
healthy donors. Flow cytometry analysis of membrane-bound Pr3 on mPr3high quiescent blood 
neutrophils (D) and triggered neutrophils (E) before (gray peak) and after (black peak) incubation 
with α1-Pi; quiescent and triggered neutrophils before (gray) and after (black) incubation with elafin 
(F-G);  triggered neutrophils before (gray) and after (black) incubation with MeO-Suc-AAPA-CMK 
(C). The control isotype is depicted by a gray line (D-G). Neutrophils were labelled with MCPR3-2 
mAb and revealed by FITC-conjugated anti-mouse IgG to visualize cell surface Pr3. The 
displacement of fluorescence in (E) shows that induced Pr3 is removed from the cell surface by α1-
Pi but not by elafin (G) and by MeO-Suc-AAPA-CMK (C), while constitutive Pr3 is not (C). 
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